1 TITLE

- 2 Protocol for the Redefining Maternal Anemia in Pregnancy and Postpartum (ReMAPP) study: A 3 multisite, international, population-based cohort study to establish global hemoglobin thresholds 4 for maternal anemia 5 SHORT TITLE 6 Protocol for the Redefining Maternal Anemia in Pregnancy and Postpartum (ReMAPP) study 7 **AUTHORS** 8 **AKU** (Zahra Hoodbhoy¹, Aneeta Hotwani¹, Fyezah Jehan¹, Amna Khan¹, Imran Nisar¹, Nida 9 Yazdani¹), **CMC** (Santosh Joseph Benjamin², Anne George Cherian², Venkata Raghava 10 Mohan², Sunitha Varghese², Balakrishnan Vijayalekshmi²), CU (Blair J. Wylie³), Dr. Dang's Lab 11 (Leena Chatterjee⁴, Arjun Dang⁴, R Venketeshwar⁴), **GW** (Sasha G. Baumann⁵, Christopher 12 Mores⁵, Qing Pan⁵, Emily R. Smith^{5*}), **HSPH** (Christopher R. Sudfeld⁶), **KEMRI** (Victor Akelo^{7,8}, 13 □Winnie K. Mwebia⁸, Kephas Otieno⁸, Gregory Ouma⁸, Harun Owuor⁸, Joyce Were⁸), KHRC 14 (Dennis Adu-Gyasi⁹, Veronica Agyemang⁹, Kwaku Poku Asante^{9*}, Sam Newton⁹, Charlotte 15 Tawiah⁹), **SAS** (Arun Singh Jadaun¹⁰, Sarmila Mazumder¹⁰, Neeraj Sharma¹⁰), **UAB** (Lynda G. 16 Ugwu¹¹), **UG** (Amma Benneh-Akwasi Kuma¹²), **UNC** (Bethany Freeman¹³, Margaret P. Kasaro¹³, 17 ¹⁴, Felistas M. Mbewe¹⁴, Humphrey Mwape¹⁴, Rachel S. Resop¹⁴, M. Bridget Spelke^{13, 14})
- 18 Authors are listed in alphabetical order first by affiliated institution and then by last name.

19 **AFFILIATIONS**

- 20 ¹Department of Paediatrics and Child Health, Aga Khan University, Karachi, Pakistan
- 21 ²Christian Medical College Vellore, Vellore, India
- ³Department of Obstetrics and Gynecology, Columbia University Medical Center, NY, United
- 23 States
- 24 ⁴Dr. Dangs Lab, New Delhi, India
- ⁵Department of Global Health, George Washington University, Washington, DC, United States

- ⁶Department of Global Health, Harvard T.H. Chan School of Public Health, Cambridge, MA,
- 27 United States
- 28 ⁷Kenya Medical Research Institute, Kisumu, Kenya
- ⁸Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, England
- ⁹Kintampo Health Research Centre, Research and Development Division, Ghana Health
- 31 Service, Kintampo North Municipality, Bono East Region, Ghana
- 32 ¹⁰Society for Applied Studies, New Delhi, India
- 33 ¹¹Department of Maternal-Fetal Medicine, University of Alabama at Birmingham School of
- 34 Medicine, Birmingham, AL, United States
- ¹²Department of Hematology, College of Health Sciences, University of Ghana, Accra, Ghana
- ¹³Department of Obstetrics and Gynecology, School of Medicine, University of North Carolina,
- 37 Chapel Hill, NC
- 38 ¹⁴University of North Carolina—Global Projects Zambia, Lusaka, Zambia

39 CORRESPONDING AUTHORS

- 40 *Kwaku Poku Asante
- 41 Kintampo Health Research Centre, Kintampo, Ghana
- 42 kwakupoku.asante@kintampo-hrc.org
- 43 *Emily R. Smith
- 44 The George Washington University, Washington D.C., USA
- 45 emilysmith@gwu.edu
- 46 **KEYWORDS**
- 47 hemoglobin; pregnancy; anemia; micronutrient deficiency; thresholds

48 ABSTRACT

Background: Anemia affects one in three pregnant women worldwide, with the greatest burden in South Asia and sub-Saharan Africa. During pregnancy, anemia has been linked to an increased risk of adverse maternal and neonatal health outcomes. Despite widespread recognition that anemia can complicate pregnancy, critical gaps persist in our understanding of the specific causes of maternal anemia and the cutoffs used to diagnose anemia in each trimester and in the postpartum period.

55 Methods and analysis: The Redefining Maternal Anemia in Pregnancy and Postpartum 56 (ReMAPP) study is a multisite, prospective, cohort study nested within the Pregnancy Risk, Infant 57 Surveillance, and Measurement Alliance (PRISMA) Maternal and Newborn Health study. 58 Research sites are located in Kenya, Ghana, Zambia, India, and Pakistan. Participants are up to 59 12,000 pregnant women who provide serial venous blood samples for hemoglobin assessment 60 at five time points: at <20 weeks, 20 weeks, 28 weeks, and 36 weeks gestation and at six weeks 61 postpartum. We will use two analytical approaches to estimate hemoglobin thresholds for defining 62 anemia: (1) clinical decision limits for cutoffs in each trimester and at six weeks postpartum based 63 on associations of hemoglobin levels with adverse maternal, fetal, and neonatal health outcomes 64 and (2) reference limits for gestational-week-specific cutoffs and at six weeks postpartum for mild, 65 moderate, and severe anemia based on tail statistical percentiles of hemoglobin values in a 66 reference (i.e., clinically healthy) subpopulation. We will also conduct biomarker-intensive testing 67 among a sub-sample of participants in each trimester to explore underlying contributing factors of 68 maternal anemia.

Ethics and dissemination: The study received local and national ethical approvals from all
 participating institutions. Findings from multisite analyses will be published among open-access,
 peer-reviewed journals and disseminated with local, national, and international partners.

72 **Registration**: ClinicalTrials.gov (ID: PRISMA-MNH 2022; NCT05904145)

73 Strengths and limitations:

- Novel study design to allow multiple analytical approaches (clinical decision limits and
 reference limits) in the same population to establish hemoglobin thresholds.
- Use of gold standard methods and external quality assurance programs to ensure
 harmonized hemoglobin measurement across sites.
- Inclusion of biomarker-intensive study arm to examine the etiology of anemia among
 pregnant women.
- All data is contributed by populations historically underrepresented in research in low- and
- 81 middle-income countries.

82 INTRODUCTION

Anemia is a common health condition characterized by low blood hemoglobin concentration 83 84 and/or low red blood cell count. Women, particularly those who are pregnant and lactating, are 85 physiologically at a higher risk than men of being anemic [1,2]. An estimated 36% of pregnant 86 women globally are anemic, with the highest prevalence in South Asia (48%) and West and 87 Central Africa (52%) [3]. Although there are many causes of anemia, iron deficiency is estimated 88 to account for roughly half of anemia cases in women [4]. Other contributing causes of anemia 89 include infectious diseases (e.g., hookworm, malaria, schistosomiasis, HIV), gynecologic 90 conditions (e.g., abnormal uterine bleeding, hemorrhage, uterine fibroids), other micronutrient 91 deficiencies (e.g. folate, vitamin B12), thyroid dysfunction, chronic kidney disease, 92 hemoglobinopathies like sickle cell disease or thalassemia, and environmental exposures such 93 as lead or arsenic [1,2,5–8]. Importantly, causes of anemia vary widely by geography, life stage, 94 and age.

95 During pregnancy, abnormal hemoglobin levels are linked to an increased risk of adverse 96 maternal, fetal and neonatal health outcomes. Specifically, maternal anemia (i.e. low hemoglobin) 97 can increase risk of postpartum hemorrhage, preeclampsia, maternal mortality, postpartum 98 maternal depression, preterm delivery, low birth weight, small for gestational age, stillbirth, 99 neonatal mortality, and poor infant brain structural development [9-13]. The likelihood of these 100 outcomes depends on the case severity, gestational timing onset and duration of anemia [11,12]. 101 Multiple studies have also observed an association between high hemoglobin concentration and 102 pregnancy complications, though there are no standard thresholds to define excess hemoglobin 103 [11,14–16]. In a systematic review and meta-analysis by Young et al. (2023), hemoglobin levels 104 greater than 13.0 g/dL during pregnancy were associated with increased risk of small-forgestational-age, stillbirth, (very) low birth weight, preterm birth, gestational diabetes, 105 106 preeclampsia, and maternal mortality [17].

107 A growing body of evidence over the last decade suggests that the hemoglobin cutoffs used to 108 diagnose anemia during pregnancy and the postpartum period should be reevaluated in 109 consideration of data from low- and middle-income countries (LMICs) [11,18-20]. In 2017, a 110 World Health Organization (WHO) technical consultation concluded that the current hemoglobin 111 thresholds used in pregnancy were not supported by sufficient data, not proven to be linked to 112 health outcomes, not representative of diverse geographies and ethnicities, and not necessarily 113 applicable in the context of common gene mutations that affect hemoglobin function [21]. Although 114 WHO released revised anemia definitions in 2024, the use of trimester-specific cutoffs during 115 pregnancy and of non-pregnant adult cutoffs in the immediate postpartum period to diagnose 116 anemia are not well-evidenced [22]. Similarly—given that causes of anemia are varied in severity, 117 multifactorial, and regionally distinct-further research is needed to understand how anemia 118 etiology differs for pregnant women, given that most research to date has focused on non-119 pregnant women [23].

120 Correct anemia identification carries significance not only for its prevention, diagnosis, and 121 treatment at the individual level, but also for tracking progress toward global anemia reduction 122 targets. Hemoglobin thresholds to diagnose anemia in pregnancy at all gestational ages were first 123 established by the World Health Organization (WHO) in 1959 as <10.0 g/dL, then adapted in 1968 124 to <11.0 g/dL [24.25]. These definitions of anemia were based on a 'normal range' of hemoglobin 125 values; wherein below the 2.5th percentile (-2 standard deviations (SDs) from the mean) is 126 considered low hemoglobin (i.e. anemia) and above the 97.5th percentile (+2 SDs from the mean) 127 is high hemoglobin. Data informing the 'normal range' was largely derived from four published 128 studies in high-income countries (Norway, England, Wales, United States) with small sample 129 sizes, not all of which included women [26-29]. In 1989, the Centers for Disease Control (CDC) 130 set thresholds based on studies in Europe and the United States for each trimester: <11.0 g/dL 131 in the first and third trimesters and <10.5 g/dL in the second trimester [30]. The WHO introduced

thresholds for anemia severity in pregnant women in 2011, adopted the CDC trimester-specific
thresholds in 2016, and added trimester-specific severity cutoffs in 2024 (**Table 1**) [22,31,32].
Notably, the WHO guidelines released in 2024 excluded data from LMICs in the pooled analysis
that informed the update, citing that the unknown effect of infection and inflammation on
hemoglobin coupled with their high prevalence in these settings precluded their inclusion [22].

Population	Hemoglobin threshold (g/dL)			
· _	Any anemia	Mild anemia	Moderate anemia	Severe anemia
Non-pregnant women	<12.0	11.0 - 11.9	8.0 - 10.9	<8.0
Pregnant women	-	-	-	-
1st trimester (≤13 weeks)	<11.0	10.0 - 10.9	7.0 - 9.9	<7.0
2nd trimester (14-27 weeks)	<10.5	9.5 - 10.4	7.0 - 9.4	<7.0
3rd trimester (≥28 weeks)	<11.0	10.0 - 10.9	7.0 - 9.9	<7.0

137 Table 1. WHO (2024) thresholds for anemia for non-pregnant and pregnant women

138 We designed the Redefining Maternal Anemia in Pregnancy and Postpartum (ReMAPP) study to 139 establish hemoglobin cutoffs using multiple analytical approaches for the diagnosis of anemia 140 during pregnancy and within 42 days postpartum in LMIC populations. The specific aims are 141 threefold: (1) to determine trimester-specific and postpartum hemoglobin thresholds for anemia 142 diagnosis based on statistically significant increased risks of adverse maternal, fetal, and newborn 143 health outcomes (i.e. decision limits); (2) to estimate gestational-week-specific and six-week 144 postpartum hemoglobin thresholds for mild, moderate, and severe anemia diagnosis using the 145 5th and 2.5th statistical percentiles among a clinically healthy subpopulation (i.e. reference limits); 146 (3) to describe the underlying contributing factors of anemia (i.e. etiology) in pregnancy in Ghana, 147 Kenya, Zambia, Pakistan, and India.

148 MATERIALS AND METHODS

149 Study design

150 ReMAPP is a prospective cohort study in five countries. It is embedded within the Pregnancy 151 Risk, Infant Surveillance, and Measurement Alliance (PRISMA) Maternal and Newborn Health 152 study: a longitudinal, open cohort study that seeks to evaluate pregnancy risk and health and 153 development for women and infants [33]. The population for ReMAPP is nested in the PRISMA 154 study cohort. Enrollment for ReMAPP was initiated on a rolling basis by site and began between 155 September 2022 and December 2023 (22 September 2022 in Pakistan, 15 December 2022 in 156 Zambia, 28 December 2022 in Ghana, 14 April 2023 in Kenya, 20 June 2023 in India (Vellore), 157 and 12 December 2023 in India (Hodal). Enrollment is expected to be completed by June 2025. 158 As illustrated in Figure 1, further selection will be done from the primary cohort of enrolled 159 participants to identify a clinically 'healthy' analytical subcohort and cross-sectional sub-samples 160 for etiology assessment. Data from the primary cohort, analytical subcohort, and cross-sectional 161 sample will be used to achieve aims one, two, and three, respectively.

162 Figure 1. Nested ReMAPP study design with estimated 12,000 pregnancies in study cohort

163 (n=1,650 to 2,000 each site)

164 Study setting

This study focuses on countries in South Asia and sub-Saharan Africa with high anemia prevalence [34]. There are six research sites: Kintampo, Ghana; Kisumu and Siaya, Kenya; Lusaka, Zambia; Karachi, Pakistan; Vellore, India; and Hodal, India. Each site has identified and mapped geographic catchment areas, which have at least 1500 deliveries per year.

169 Eligibility criteria and recruitment

Participants eligible for the ReMAPP study are pregnant women who live within the catchment
area, are <45 years and meet country-specific minimum age requirements (Ghana: 15 years of

age; Kenya: 18 years of age or emancipated minors; Pakistan: 15 years of age or emancipated
minors; Zambia: 15 years of age; India: 18 years of age), have a viable intrauterine pregnancy,
are less than 20 weeks gestation as verified via ultrasound, intend to stay in the study area until
six weeks post-delivery, and who provide informed consent.

176 Participant selection and sampling

All participants enrolled in the PRISMA study will be invited to participate in the ReMAPP study if they meet eligibility criteria. Enrollment will continue until the target sample size (n=1650 to 2000 per site) is achieved. These participants will form the ReMAPP primary cohort, and will undergo serial hemoglobin testing by complete blood count and be followed up at regular study visits through one year postpartum.

182 Upon enrollment, all ReMAPP participants will undergo screening based on predetermined criteria 183 obtain sociodemographic information, obstetric history, vital signs, anthropometric to 184 measurements, and laboratory results. If a participant meets the 21 screening criteria (**Box 1**), 185 they will be included in the clinically 'healthy' analytical subcohort. Selected participants may also 186 be excluded from the final 'healthy' analytical subcohort if any of the following occur during follow-187 up: multiple pregnancies previously not identified, severe conditions not initially evident including 188 cancer, HIV, tuberculosis, or malaria, or severe pregnancy-related conditions requiring hospital 189 admission including severe preeclampsia/eclampsia.

190 Box 1. Screening criteria for clinically healthy subcohort

- 1. Aged 18 to 34 years
- 2. Gestational age at enrollment <14 weeks
- 3. Pre-pregnancy or early pregnancy body mass index (BMI) of >18.5 and <30 kg/m²
- 4. Mid-upper arm circumference >23cm
- 5. Height ≥150 cm
- 6. Singleton pregnancy
- 7. Systolic blood pressure <140 mmHg and diastolic blood pressure <90 mmHg
- 8. No iron deficiency (serum ferritin >15 mcg/L adjusted for inflammation [35])
- 9. No subclinical inflammation (CRP≤5 mg/L and/or AGP≤1 g/L)

- No hemoglobinopathies (SS, SC, SE, EE, CC, SD-Punjab, Sβthal, Eβthal, Cβthal, CD-Punjab, ED-Punjab, D-D-Punjabβthal, Thalassemia major, Thalassemia intermedia, or Alpha thalassemia)
- 11. Normal glucose-6-phosphate dehydrogenase (≥6.1 U/g Hb)
- 12. No reported previous low birth weight delivery
- 13. No reported previous stillbirth
- 14. No reported previous unplanned cesarean delivery
- 15. No reported cigarette smoking, tobacco chewing, or betel nut use
- 16. No reported alcohol consumption during pregnancy
- 17. No current malaria infection (per rapid diagnostic test)
- 18. No current Hepatitis B virus infection (per rapid diagnostic test)
- 19. No current Hepatitis C virus infection (per rapid diagnostic test)
- 20. No known history or current chronic disease (cancer, kidney disease, or cardiac condition)
- 21. No known history or current HIV

191 Among the participants screened, a cross-sectional sample of up to 300 participants (100 per

- trimester, both anemic and nonanemic) per site will be selected to undergo biomarker-intensive
- 193 testing. Any method of population-representative sampling may be used within each trimester
- 194 stratum, provided that selection occurs over the same time period to eliminate time bias.

195 Follow-up procedures and data collection

196 Data will be collected using a harmonized set of forms developed for the PRISMA study [33]. 197 Beyond the routine PRISMA study visit procedures, ReMAPP participants will provide biological 198 specimens to undergo additional laboratory testing (Table 2). For hemoglobin, the primary 199 measure of interest, participants will be serially assessed at less than 20 weeks, at 20 weeks, 28 200 weeks, and 36 weeks gestation and at six weeks postpartum by complete blood count using a 201 venous blood sample and a five-part differential automated hematology analyzer. Additional 202 testing will be done at enrollment, as a part of the screening laboratory tests for the clinically 203 'healthy' subcohort. Biomarker-intensive testing will be done for the sample of 300 participants 204 (100 per trimester), either during their enrollment visit (gestational age less than 14 weeks), 20-205 week, or 32-week ANC visit. Methods and timing of laboratory assessments will be standardized 206 across sites to ensure comparability and guality.

207 Table 2. Laboratory tests for the ReMAPP study

Condition	Assessment	Method
-----------	------------	--------

Anemia	Hemoglobin*	Complete blood count using five-part differential hematology analyzer
Screening tests	at enrollment (<20 weeks gestation) to iden	tify clinically healthy subcohort
Iron deficiency	Ferritin	ELISA¹ (Quansys Q-plex™ Human Micronutrient v2 (7-plex))
	Serum transferrin receptor	ELISA¹ (Quansys Q-plex™ Human Micronutrient v2 (7-plex))
Inflammation	C-reactive protein	ELISA¹ (Quansys Q-plex™ Human Micronutrient v2 (7-plex))
	Alpha 1-acid glycoprotein	ELISA¹ (Quansys Q-plex™ Human Micronutrient v2 (7-plex))
Communicable diseases	HIV	Rapid diagnostic test
	Malaria	Rapid diagnostic test
	Hepatitis B and C	Rapid diagnostic test
Red blood cell defects	Sickle cell disease	HPLC ²
	Beta (β) and alpha (α) thalassemias	HPLC ²
	Glucose-6-phosphate dehydrogenase	SD Biosensor Standard G6PD Analyzer
Biomarker-inter	nsive tests at <14, 20, or 32 weeks gestation	for random sample
Iron deficiency	Hepcidin	ELISA ¹
	Total iron-binding capacity	Colorimetric chemistry analyzers
Other	Vitamin A serum retinol	HPLC ²
micronutrient deficiency	Vitamin B12 total cobalamin	ECLIA ³
	Vitamin B12 holotranscobalamin II	Abbexa HoloTC ELISA ¹
	Folate	Microbiologic assay
	Zinc	ICP-MS ⁴ or AAS ⁵
Red blood cell parameters	Red blood cell count	Five-part differential hematology
	Hematocrit	- analyzer
	Mean corpuscular volume	-
	Mean corpuscular hemoglobin concentration	-

	Red cell distribution width		
	Red blood cell morphological abnormalities	Leishman, Wright-Giemsa, or Giemsa	
	White blood cell morphological abnormalities		
	Platelet morphological abnormalities	-	
	Presence of blood parasites	-	
Communicable diseases	Syphilis	Rapid diagnostic test	
	HIV	Rapid diagnostic test	
	Hepatitis B and C	Rapid diagnostic test	
	Malaria	Rapid diagnostic test	
		Placental tissue histopathology	
		Leishman, Giemsa stain, or Quantitative Buffy Coat for microscopy	
	Tuberculosis	GeneXpert (4-module, 8-module, or 24-module)	
	Schistosomiasis	Kato-Katz coproscopy, PCR ⁶ test, or urine filtration	
	Soil-transmitted helminths	Kato-Katz coproscopy	
Non- communicable diseases	Urinalysis	Dipstick	
	Renal function	Colorimetric chemistry analyzer	
	Liver function	Colorimetric chemistry analyzer	
	Blood lead	ICP-MS ⁴ or AAS ⁵	

208 ¹Enzyme-linked immunoassay (ELISA)

209 ²High-performance liquid chromatography (HPLC)

210 ³Electrochemiluminescence (ECLIA)

211 ⁴Inductively coupled plasma mass spectrometry (ICP-MS)

212 ⁵Atomic Absorption Spectrophotometry (AAS)

213 ⁶Polymerase chain reaction (PCR)

214 Quality assurance for laboratory tests

215 Each site laboratory will adhere to the Laboratory Quality Assurance and Quality Control Standard

216 Operating Procedures manual developed specifically for this study. For full blood count

217 measurement, all participating labs will be enrolled onto the United Kingdom National External

218 Quality Assurance Scheme for Hematology for monthly quality assurance [36]. For full blood count 219 and all other analytes, the College of American Pathologists' External Quality Assessment 220 Program is required [37].

221 Sample size estimates

Each site will enroll 1,650 to 2,000 participants in the ReMAPP study, to achieve an overall study sample of 12,000 participants across the six sites. The sample size was selected assuming that about 30% (n=600) will meet the eligibility criteria for the 'healthy' subcohort. This sample size will also capture sufficient cases of the primary maternal and newborn outcomes of interest, based on previous regional prevalence estimates, in order to conduct a pooled decision limits analysis with at least 90% power to estimate association between anemia and each outcome.

228 Our power speculation is based on the distribution of hemoglobin values in pregnancy by 229 gestational age presented in the INTERGROWTH-21st study [18]. For the 'healthy' analytical 230 subcohort, a sample size of 600 participants per site allows for single-site estimation of 231 hemoglobin thresholds for any maternal anemia (i.e., 5th percentile) and severe maternal anemia 232 (i.e., 2.5th percentile). As illustrated in Figure 2, there will be sufficient precision to distinguish 233 between these two percentiles without overlapping 95% confidence intervals. If sites are unable 234 to identify 600 participants for the healthy cohort, a minimum sample size of 300 participants will 235 be sufficient for single-site hemoglobin threshold estimation.

Figure 2. Visualization of sample size estimates with thresholds for any (i.e. 5th

percentile) and severe maternal anemia (i.e. 2.5th percentile) at n = 300, 400, 500, 600

For the cross-sectional sample, n=300 was determined to minimize the burden of additional specimen collection while allowing for exploratory pooled analyses of anemia etiology. The calculation is based on the following assumptions: one third of the participants have a certain contributing factor (e.g., the prevalence of vitamin A insufficiency); 30% of participants without the

factor have anemia; and 50% with the factor have anemia. At the two-sided significance level of 95% and 80% statistical power, we can detect a prevalence ratio of 1.7 with a sample size of between 240 and 270 [38]. We inflated the sample to 300 to account for the fact that some contributing factors are less prevalent in certain study sites.

246 Participant and public involvement

247 Participants will be collaboratively involved at multiple phases of the study. During initial protocol 248 workshops, investigators carefully evaluated the additional burden of study participation; for this 249 reason, the size of the biomarker-intensive sample was kept to a minimum and invasive blood 250 draws limited to select visit timepoints. As a part of the translation and validation process for 251 questionnaires to measure fatigue, patients' experiences were centered and informed scale 252 validation procedures. Participants' health priorities and experiences will also be explored in 253 corresponding qualitative research about maternal morbidity. Upon completion of the study, we 254 intend to share the main findings with participants and community members via appropriate local 255 dissemination methods. Finally, we will ensure that participants' contributions to this research are 256 acknowledged in any subsequent reports, presentations, and publications.

257 Ethical and safety considerations

258 This protocol, the informed consent documents and any subsequent modifications will be 259 reviewed and approved by the relevant institutional review board (IRB) and ethics review 260 committee (ERC) responsible for oversight of the study at each site. IRB approvals for this 261 research were received from the following ERCs in each country: Ghana (Ghana Health Service 262 ERC (FWA No. 000200025) and the Kintampo Health Research Center Institutional Ethics 263 Committee, FWA No. 00011103), Kenya (KEMRI Scientific and Ethics Review Unit, 04-10-358-264 4166), Zambia (University of Zambia Biomedical Research Ethics Committee, IRB00001131 of 265 IORG0000774 and UNC Biomedical IRB 356795), India (Office of Research, Christian Medical

266 College, Vellore, India Ethics Committee, IRB14553), India (Ethics Review Committee, Society 267 for Applied Studies, New Delhi, SAS/ERC/ReMAPP Study/2022; Department of Health Research, 268 EC/NEW/INST/2022/DL/0140), Pakistan (National Institutes of Health - Health Research Institute, 269 National Bioethics Committee Ref: No.4-87/NBC-962/23/593 and Aga Khan University Ethics 270 Review Committee, 2022-7197-21350), and the United States (Columbia University IRB IRB-271 AAAU7504: The George Washington University IRB NCR224396: Harvard University IRB IRB-272 23-1093). The rights and safety of all study participants will be protected. Written informed 273 consent, assent and parental consent will be sought from all study participants as appropriate 274 prior to enrollment. Site-specific unique identification numbers will be issued to participants 275 instead of names to protect their identity. A limited data set will be stored in a secure cloud server 276 where only trained study staff will have credentials for access. Study participants with abnormal 277 biochemical results will be referred for further clinical assessment and management according to 278 study-specific standard operating procedures.

279 ANALYTICAL PLAN

Aim 1: Establishing hemoglobin clinical decision limits based on adverse outcomes

281 Aim 1 will establish trimester-specific and postpartum hemoglobin clinical decision limits for any 282 anemia based on associations with adverse maternal, fetal, and infant outcomes (Table 3). For 283 this analysis, hemoglobin and outcome data points from all participants will be pooled. 284 Nonparametric relationships between risks of adverse events and hemoglobin levels will be 285 plotted using real data [39]. A series of candidate thresholds in hemoglobin values will be 286 considered and disease risks before and after each threshold will be compared. Thresholds with 287 clinically meaningful differences in the disease risks and statistically sound significance levels will 288 be selected. Clinical decision limits for overall adverse events will be reported, as well as disease-289 specific clinical decision limits.

Outcome	Definition	Timing	
Primary outcomes			
Severe maternal outcomes	Composite of maternal deaths, late maternal deaths, and near-misses	Pregnancy through 1 year postpartum	
Maternal death	Death from any cause related to or aggravated by pregnancy or its management (excluding accidental or incidental causes)	Pregnancy through 42 day postpartum	
Perinatal depression	Likelihood of depression per the Edinburgh Postnatal Depression Scale	At 20 weeks and 32 weeks gestation; at 6 weeks postpartum	
Postpartum anemia	Low hemoglobin concentration <12 g/dL	6 weeks and 6 months	
Preterm birth	Delivery prior <37 weeks of gestation of a live born infant	<37 weeks gestation	
Small for gestational age ¹	Birthweight of lower than the sex-specific 10th percentile for each week of gestational age, according to the sex- specific INTERGROWTH reference standards	Delivery	
Stillbirth	Delivery of a fetus showing no signs of life or >350g birth weight, if gestational age is unavailable	≥20 weeks gestation	
Secondary outcomes			
Late maternal death	Death from any cause related to or aggravated by pregnancy or its management (excluding accidental or incidental causes)	From 42 days to 1 year postpartum	
Preeclampsia	For participants without preexisting hypertension, defined as gestational hypertension AND gestational proteinuria OR development of severe features. For participants with chronic hypertension, defined as gestational proteinuria OR development of severe features	>20 weeks gestation to 42 days postpartum	
Hemorrhage	Antepartum hemorrhage (APH): bleeding from or into the genital tract during pregnancy. Postpartum hemorrhage (PPH): estimated blood loss of ≥500 mL, clinical diagnosis of PPH, or receipt of a procedure to manage PPH (including blood transfusion).	≥24 weeks gestation and prior to delivery (APH), within 24 hours after birth (PPH)	

290 Table 3. Primary and secondary health outcomes for establishing decision limits

Preterm premature rupture of membranes	Rupture of membranes before the onset of labor	<37 weeks of gestation
Maternal sepsis	Organ dysfunction resulting from infection	Pregnancy, delivery, and up to 42 days postpartum
Maternal fatigue ²	Decreased capacity for physical and mental activity after childbirth, a persistent lack of energy, impairments in concentration and attention not easily relieved by rest or sleep	At 20 weeks and 32 weeks gestation; at 6 weeks postpartum
Low birthweight	Liveborn infant weighing less than 2500 g at birth	Within 72 hours of delivery
Neonatal hyperbilirubinemia	Presence of excess bilirubin. Calculated in line with the age-specific total bilirubin thresholds per the American Academy of Pediatrics BiliTool [™] algorithm [40]	Birth to 7 days
Possible severe bacterial infection	Presence of any of the following signs or symptoms: Not able to feed at all or not feeding well; convulsions; severe chest indrawing; high body temperature (≥38°C for <2 months, ≥37.5°C for 2+ months); low body temperature (less than 35.5°C); no movement/only when stimulated; fast breathing (≥60 BPM for <2 months, ≥50 BPM for 2+ months)	Birth to 59 days
Neonatal sepsis	Inflammatory response and organ dysfunction following presence of a severe infection from as suspected (by a clinician) or proven (with culture)	Birth to 28 days
Infant neurodevelopment ³	Infant's cognitive, motor, linguistic, and social-emotional development	At 12 months

¹Small for gestational age defined as lower than the sex-specific 10th percentile for each week of gestational age per INTERGROWTH standards [41]

293 ²Maternal fatigue assessed using the FACIT-Fatigue Scale at 20 weeks and 32 weeks gestation and six

294 weeks postpartum.

²⁹⁵ ³Infant neurodevelopment assessed using the Global Scale for Early Development Short Form.

Aim 2: Establishing hemoglobin reference limits among a healthy population

Aim 2 will establish gestational-age-specific hemoglobin reference limits for any, mild, moderate,

298 or severe anemia in a reference population (i.e., clinically 'healthy' subcohort) during pregnancy

and within 42 days postpartum [42,43]. This analysis will include hemoglobin data points from all

- 300 participants eligible for the clinically 'healthy' subcohort. Fractional polynomial regression (FPR)
- 301 will be used to model and visualize the hemoglobin changing curves of different percentiles

against gestational age [18]. Sensitivity analysis of the percentile curves predicted by FPR models
 will be performed excluding one site at a time. If the hemoglobin distributions are similar across
 sites and between-site between is less than within-site variance, we will pool the data; if not,
 analyses will remain stratified by site.

Hemoglobin levels below the 5th or 2.5th percentiles at the corresponding time points during pregnancy are typically considered abnormally low and likely indicative of anemia. Therefore, the reference limits are defined as tail percentiles of hemoglobin levels in the reference population. Tail percentiles, such as 5th or 2.5th percentiles, will be modeled as a smooth polynomial function of gestational weeks using hemoglobin levels. With the final validated model, we will estimate the 2.5th, 5th, 95th, and 97.5th percentiles predicted from the FPR curves at specific gestational timepoints from 14 to 40 weeks and postpartum.

313 Aim 3: Describing the etiology of anemia in pregnancy

314 Aim 3 will describe the underlying contributing factors of anemia in pregnancy among a sample 315 of up to 1,800 participants (up to 300 per site), with approximately equal numbers in each 316 trimester. Analyses will be performed on pooled, regional, and site-specific data to identify shared 317 and unique risk factors for anemia. We will quantify the association between contributing factors 318 and anemia (defined using the WHO cutoffs and study-established reference and decision limit 319 thresholds) by calculating relative risks from a generalized linear log-binomial model with robust 320 standard errors. If these models fail to converge, we will use modified Poisson estimates, which 321 produce valid but less efficient estimates of the log-binomial model. We will run separate models 322 for proximal, medial, and distal risk factors (Figure 3). Distal risk factors will be included as 323 potential confounders to proximal and medial models. We will estimate the population attributable 324 risk fraction using prevalence of the exposure/risk factor and the relative risk of anemia in the 325 exposed versus unexposed group. Partial population attributable risk will be calculated by fitting 326 multivariate models with log link for anemia adjusting for multiple risk factors. For contributing

factors significantly associated with risks of anemia, we will further report the change incontinuous hemoglobin concentrations associated with the factor.

329 Figure 3. Risk factors of maternal anemia

330 **Dissemination plan**

331 The data generated in the course of the study will be reviewed on a regular basis for guality per 332 our established Data Quality Assurance and Quality Control Standard Operating Procedures 333 monthly. Following the end of the study, meetings will be organized at each study site to share 334 results with community members, local authorities, and study participants. Findings will also be 335 shared with local and international stakeholders, including the Bill & Melinda Gates Foundation, 336 WHO, CDC, United States Agency for International Development, and Ministries of Health in each 337 participating country. Abstracts will be developed for dissemination through both local and 338 international scientific conferences and publication in peer-reviewed journals.

339 AUTHORS' CONTRIBUTIONS

340 Conceptualization: VA, KPA, AGC, ZH, FJ, MPK, SM, VRM, CM, IN, QP, ERS, MBS, and CRS. 341 Funding acquisition: KPA, CT, SN, VA, SJB, IN, MPK, MBS, ERS, CM, and SM. Design of 342 methodology: KPA, CT, ABAK, ERS, QP, LGU, CRS, and BJW. Project administration: VA, DAG, 343 SGB, BF, ASJ, AK, FMM, HM, KO, RSR, WKM, GO, HO, NS, BV, SV, ZAW, JW, and NY. 344 Provision of study materials: VA, DAG, LC, AD, AH, HM, KO, RR, RV, and BV. Supervision: VA, 345 KPA, SJB, ZH, FJ, ASJ, MPK, SM, VRM, CM, WKM, SN, IN, QP, NS, ERS, MBS, CRS, CT, and 346 LGU. Visualization: SGB, QP, and ERS. Writing—original draft preparation: VA, KPA, SGB, QP, 347 and ERS. Writing-review and editing: VA, VA, KPA, SGB, SJB, LC, AGC, AD, DAG, AH, BF, 348 ZH, ASJ, FJ, ABAK, AK, MPK, CM, VRM, HM, SM, IM, FMM, WKM, SN, GO, KO, HO, QP, RSR, 349 NS, ERS, MBS, CRS, CT, LGU, BV, RV, SV, BJW, JW, NY.

350 FUNDING STATEMENT

- This work was supported by Bill and Melinda Gates Foundation grant number [INV-002220 and INV-037626 to KPA, CTA, and SN; INV-003601 to VA; INV-043092 to SB; INV-005776 to IN and ZH; INV-057218 to MPK; K01TW012426 NIH/FIC to MBS; INV-041999 and INV-031954 to ERS; INV-060797 to CM; and INV-057223 to SM]. The funders provided input on the design of the study
- but had no role in the decision to publish or preparation of the manuscript.

356 **ACKNOWLEDGEMENTS**

357 This study would not be possible without the support of the Bill & Melinda Gates Foundation,

358 specifically from Laura Lamberti and Sun-Eun Lee. The study design greatly benefited from the

359 expertise of the ReMAPP Technical Advisory Group members, who were generous with their time

360 and expertise: Lisa Rogers, Maria Elena Jefferds, Denish Moorthy, Melissa Fox Young, Nicholas

361 Kassebaum, Eric Ohuma, and Bosede Afolabi. ReMAPP investigators are grateful to the

362 extensive network of individuals and organizations who contributed to the design of this study,

363 including but not limited to biostatisticians, laboratory technicians, obstetricians, community health

364 workers, field data collectors, and research partners.

365 **COMPETING INTERESTS STATEMENT**

366 The authors declare no competing interests.


367 **REFERENCES**

- Kassebaum NJ, Jasrasaria R, Naghavi M, Wulf SK, Johns N, Lozano R, et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood. 2014;123: 615–624.
- Anemia in Pregnancy: ACOG Practice Bulletin, Number 233. Obstet Gynecol. 2021;138:
 e55–e64.
- Stevens GA, Paciorek CJ, Flores-Urrutia MC, Borghi E, Namaste S, Wirth JP, et al.
 National, regional, and global estimates of anaemia by severity in women and children for
 2000-19: a pooled analysis of population-representative data. Lancet Glob Health. 2022;10:
 e627–e639.
- 4. Safiri S, Kolahi A-A, Noori M, Nejadghaderi SA, Karamzad N, Bragazzi NL, et al. Burden of

- anemia and its underlying causes in 204 countries and territories, 1990-2019: results from
 the Global Burden of Disease Study 2019. J Hematol Oncol. 2021;14: 185.
- 5. Yang Y, Hou Y, Wang H, Gao X, Wang X, Li J, et al. Maternal Thyroid Dysfunction and Gestational Anemia Risk: Meta-Analysis and New Data. Front Endocrinol . 2020;11: 201.
- Deng Y, Steenland K, Sinharoy SS, Peel JL, Ye W, Pillarisetti A, et al. Association of
 household air pollution exposure and anemia among pregnant women: Analysis of baseline
 data from "Household Air Pollution Intervention Network (HAPIN)" trial. Environ Int.
 2024;190: 108815.
- 385
 7. Yadav G, Chambial S, Agrawal N, Gothwal M, Kathuria P, Singh P, et al. Blood lead levels
 in antenatal women and its association with iron deficiency anemia and adverse pregnancy
 outcomes. J Family Med Prim Care. 2020;9: 3106–3111.
- Ortiz-Garcia NY, Cipriano Ramírez AI, Juarez K, Brand Galindo J, Briceño G, Calderon
 Martinez E. Maternal Exposure to Arsenic and Its Impact on Maternal and Fetal Health: A
 Review. Cureus. 2023;15: e49177.
- Azami M, Badfar G, Khalighi Z, Qasemi P, Shohani M, Soleymani A, et al. The association
 between anemia and postpartum depression: A systematic review and meta-analysis.
 Caspian J Intern Med. 2019;10: 115–124.
- Kang SY, Kim H-B, Sunwoo S. Association between anemia and maternal depression: A
 systematic review and meta-analysis. J Psychiatr Res. 2020;122: 88–96.
- 396 11. Young MF, Oaks BM, Tandon S, Martorell R, Dewey KG, Wendt AS. Maternal hemoglobin
 397 concentrations across pregnancy and maternal and child health: a systematic review and
 398 meta-analysis. Ann N Y Acad Sci. 2019;1450: 47–68.
- 399 12. Sukrat B, Wilasrusmee C, Siribumrungwong B, McEvoy M, Okascharoen C, Attia J, et al.
 400 Hemoglobin concentration and pregnancy outcomes: a systematic review and meta-401 analysis. Biomed Res Int. 2013;2013: 769057.
- 402 13. Wedderburn CJ, Ringshaw JE, Donald KA, Joshi SH, Subramoney S, Fouche J-P, et al.
 403 Association of Maternal and Child Anemia With Brain Structure in Early Life in South Africa.
 404 JAMA Netw Open. 2022;5: e2244772.
- 405 14. Steer PJ. Maternal hemoglobin concentration and birth weight. Am J Clin Nutr. 2000;71:
 406 1285S–7S.
- 407 15. Yip R. Significance of an abnormally low or high hemoglobin concentration during
 408 pregnancy: special consideration of iron nutrition. Am J Clin Nutr. 2000;72: 272S–279S.
- 409 16. Amburgey OA, Ing E, Badger GJ, Bernstein IM. Maternal hemoglobin concentration and its
 410 association with birth weight in newborns of mothers with preeclampsia. J Matern Fetal
 411 Neonatal Med. 2009;22: 740–744.
- Young MF, Oaks BM, Rogers HP, Tandon S, Martorell R, Dewey KG, et al. Maternal low
 and high hemoglobin concentrations and associations with adverse maternal and infant
 health outcomes: an updated global systematic review and meta-analysis. BMC Pregnancy
 Childbirth. 2023;23: 264.

- 416 18. Ohuma EO, Young MF, Martorell R, Ismail LC, Peña-Rosas JP, Purwar M, et al.
- 417 International values for haemoglobin distributions in healthy pregnant women.
 418 EClinicalMedicine. 2020;29-30: 100660.
- 419 19. Chang S-C, O'Brien KO, Nathanson MS, Mancini J, Witter FR. Hemoglobin concentrations
 420 influence birth outcomes in pregnant African-American adolescents. J Nutr. 2003;133:
 421 2348–2355.
- 422 20. Yip R. Significance of an abnormally low or high hemoglobin concentration during
 423 pregnancy: special consideration of iron nutrition. Am J Clin Nutr. 2000;72: 272S–279S.
- 424 21. Garcia-Casal MN, Pasricha S-R, Sharma AJ, Peña-Rosas JP. Use and interpretation of
 425 hemoglobin concentrations for assessing anemia status in individuals and populations:
 426 results from a WHO technical meeting. Ann N Y Acad Sci. 2019;1450: 5–14.
- 427 22. Guideline on haemoglobin cutoffs to define anaemia in individuals and populations. World
 428 Health Organization; 2024 Mar. Available:
 429 https://www.who.int/publications/i/item/9789240088542
- 430 23. Chaparro CM, Suchdev PS. Anemia epidemiology, pathophysiology, and etiology in low431 and middle-income countries. Ann N Y Acad Sci. 2019;1450: 15–31.
- 432 24. World Health Organization. Iron Deficiency Anaemia: Report of a Study Group. World
 433 Health Organization Technical Report Series; 1959. Report No.: 182. Available:
 434 https://apps.who.int/iris/bitstream/handle/10665/40447/WHO_TRS_182.pdf
- 435 25. World Health Organization. WHO Scientific Group on Nutritional Anaemias & World Health
 436 Organization. Nutritional anaemias : report of a WHO scientific group [meeting held in
 437 Geneva from 13 to 17 March 1967]. 1968. Available:
 438 https://apps.who.int/iris/handle/10665/40707
- 439 26. Natvig K. Studies on hemoglobin values in Norway. V. Hemoglobin concentration and
 440 hematocrit in men aged 15-21 years. Acta Med Scand. 1966;180: 613–620.
- 441 27. Kilpatrick GS HRM. The prevalence of anaemia in the community. British Medical Journal.
 442 1961. pp. 778–782.
- 28. De Leeuw KM Lowenstein L Hsieh YS. Iron deficiency and hydremia in normal pregnancy.
 Medicine. The Wiliams & Wilkins Co.; 1966. pp. 291–315.
- 445 29. Sturgeon P. Studies of iron requirements in infants. III. Influence of supplemental iron
 446 during normal pregnancy on mother and infant. A. The mother. British Journal of
 447 Haematology. 1959.
- 30. CDC Criteria for Anemia in Children/Childbearing-Aged Women. 9 Jun 1989 [cited 9 Mar
 2021]. Available: https://wonder.cdc.gov/wonder/prevguid/p0000169/p0000169.asp
- 450 31. World Health Organization. WHO recommendations on antenatal care for a positive
 451 pregnancy experience. 2016. Available:
- 452 https://apps.who.int/iris/bitstream/handle/10665/250796/9789241549912-
- 453 eng.pdf;jsessionid=B18B1C73CA88F51F6DD4326F3906382B?sequence=1
- 454 32. World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and

- 455 assessment of severity. Vitamin and Mineral Nutrition Information System; 2011. Available:
 456 https://www.who.int/vmnis/indicators/haemoglobin.pdf
- 33. Smith ER, Baumann SG, Mores C, Tawiah C, Asante KP, Mazumder S, et al. PRISMA
 Maternal & Newborn Health Study. In: Open Science Foundation [Internet]. OSF; 1 Oct
 2024 [cited 2 Oct 2024]. Available: https://osf.io/gckyt/
- 460 34. World Health Organization. Nutritional Anaemias: Tools for Effective Prevention and461 Control. 2017.
- 35. Suchdev PS, Namaste SML, Aaron GJ, Raiten DJ, Brown KH, Flores-Ayala R, et al.
 Overview of the Biomarkers Reflecting Inflammation and Nutritional Determinants of
 Anemia (BRINDA) Project. Adv Nutr. 2016;7: 349–356.
- 465 36. Full Blood Count (FBC) Programme. In: UK NEQAS [Internet]. 6 Mar 2017 [cited 15 Jul
 466 2024]. Available: https://ukneqas.org.uk/programmes/result/?programme=full-blood-count467 %28fbc%29
- 468 37. Proficiency Testing (PT)/External Quality Assessment (EQA) Programs Process. In:
 469 College of American Pathologists [Internet]. 26 Jan 2018 [cited 15 Jul 2024]. Available:
 470 https://www.cap.org/laboratory-improvement/laboratories-outside-the-usa/proficiency471 testing-pt-external-quality-assessment-eqa-programs/proficiency-testing-pt-external-quality472 assessment-eqa-programs-process
- 473 38. Kelsey JL. Methods in Observational Epidemiology. Monographs in Epidemiology and;474 1996.
- 475 39. Lai Y. On the adaptive partition approach to the detection of multiple change-points. PLoS
 476 One. 2011;6: e19754.
- 40. Kemper AR, Newman TB, Slaughter JL, Maisels MJ, Watchko JF, Downs SM, et al. Clinical
 478 Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35
 479 or More Weeks of Gestation. Pediatrics. 2022;150. doi:10.1542/peds.2022-058859
- 480 41. Fernandes M, Villar J, Stein A, Staines Urias E, Garza C, Victora CG, et al.
 481 INTERGROWTH-21st Project international INTER-NDA standards for child development at
 482 2 years of age: an international prospective population-based study. BMJ Open. 2020;10:
 483 e035258.
- 484 42. Sikaris K. Application of the stockholm hierarchy to defining the quality of reference
 485 intervals and clinical decision limits. Clin Biochem Rev. 2012;33: 141–148.
- 486
 43. Ozarda Y, Sikaris K, Streichert T, Macri J, IFCC Committee on Reference intervals and
 487
 488
 488
 488
 488
 489
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 4



'Healthy' subcohort identified to define **reference limits** (n=600)

Random sample selected to describe **anemia etiology** (n=300, 100 per trimester)

Fig1



n=500




Fig2

Distal factors	Medial factors	Proximal factors
Socioeconomic characteristics	Micronutrient supplements and parasitic treatment	Iron and other micronutrient deficiency
Environmental conditions	Ambient air pollution	Inflammation
Season		Red cell defects and abnormal red cell morphology
		Communicable diseases
		Non-communicable diseases

